Background information
CD133, formerly known as AC133, recognizes epitope 1 of the CD133 antigen.2,3 It is a marker that is frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells. In the hematopoietic system, CD133 is expressed on a small portion of CD34– cells4 as well as on a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood, and peripheral blood5. CD133 has also been found to be expressed on circulating endothelial progenitor cells;6,7 fetal neural stem cells;8,9 other tissue-specific stem cells, such as renal10, prostate11, and corneal12 stem cells; cancer stem cells from tumor tissues; as well as ES and iPS cell-derived cells.
There is a growing interest in CD133 antigen expressing stem cells from normal blood or bone marrow in the field of regenerative medicine, for example bone marrow-derived CD133+ stem cells in cardiovascular13-17, liver, or peripheral artery diseases18-20.
The CD133 antibody included in the kit recognizes epitope CD133/1. For quality control staining of CD133-separated cells, the use of CD133/2 (293C3)-PE or -APC is recommended.
Downstream applications
Isolated from hematopoietic sources, CD133+ cells can become adherent and are reported to become CD133-negative during culture.21,22 These adherent cells can then in turn give rise to nonadherent CD133+ cells that are able to differentiate to both hematopoietic and nonhematopoietic cell types.23
CD133+ cells have shown a capacity for tissue differentiation, including to neural lineages24. CD133+ isolated from fetal liver25, umbilical cord blood26, bone marrow27, mobilized blood28, and skin29 are capable of in vitro differentiation to neuronal cells as well as to astrocytes,25,26,28 oligodendrocytes,26,28 and glial cells.26 CD133+ cells isolated from human fetal brain8,9,30-32 were able to form self-renewing neurospheres in vitro, and to differentiate into neurons8,32 and glia19,23. When injected into mice, human CD133+ cells differentiated into fully integrated neurones and glial cells9,30 as well as astrocytes and endothelial cells29. The CD34+CD133+ cell population, which includes CD34+CD38– cells, was shown to be capable of repopulating NOD/SCID mice33.
Columns
For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, D, or autoMACS Columns.
Overview
The Indirect CD133 MicroBead Kit was developed for positive selection or depletion of CD133+ cells, using a two-step procedure involving indirect magnetic labeling.
- Hematopoietic stem cells can be isolated from peripheral blood, cord blood, bone marrow, or leukapheresis product.
- Neural progenitor cells can be isolated from single-cell suspensions from primary neural tissues or cell lines.
- ES and iPS cell–derived neural, endothelial, or hematopoietic progenitors can be isolated from differentiated ES or iPS cell cultures1.
- Cancer stem cells can be isolated from single-cell suspensions from primary tumor tissue or cell lines.
